Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 12/20 | 0.71 |
| ▸ | CHEK1 | O14757 | 12/20 | 0.71 |
| ▸ | JAK2 | O60674 | 6/20 | 0.69 |
| ▸ | LCK | P06239 | 1/20 | 0.69 |
| ▸ | IGF1R | P08069 | 1/20 | 0.69 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.69 |
| ▸ | TSSK2 | Q96PF2 | 1/20 | 0.69 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.69 |
| ▸ | JAK3 | P52333 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13258885 | 0.86 | CHEK1 (0.84) | MAPKAPK2CHEK1JAK2LCKIGF1R | |
| SCHEMBL13776783 | 0.83 | CHEK1 (0.83) | MAPKAPK2CHEK1JAK2LCKIGF1R | |
| SCHEMBL13258936 | 0.83 | CHEK1 (1.00) | MAPKAPK2CHEK1JAK2LCKIGF1R | |
| SCHEMBL13258755 | 0.82 | CHEK1 (0.80) | MAPKAPK2CHEK1JAK2LCKIGF1R | |
| SCHEMBL13258758 | 0.82 | CHEK1 (1.00) | MAPKAPK2CHEK1JAK2LCKIGF1R | |
| SCHEMBL13776784 | 0.82 | CHEK1 (1.00) | MAPKAPK2CHEK1JAK2LCKIGF1R | |
| SCHEMBL13764316 | 0.82 | CHEK1 (1.00) | MAPKAPK2CHEK1JAK2LCKIGF1R | |
| SCHEMBL13258877 | 0.82 | CHEK1 (0.73) | MAPKAPK2CHEK1JAK2LCKIGF1R | |
| SCHEMBL13259783 | 0.82 | CHEK1 (1.00) | MAPKAPK2CHEK1JAK2LCKIGF1R | |
| SCHEMBL13258873 | 0.81 | CHEK1 (1.00) | MAPKAPK2CHEK1JAK2LCKIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010088368-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2010-08-05 | — | — | WO | disclosed |
| US-20090175852-A1 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION | 2009-07-09 | — | — | US | disclosed |
| US-20090175852-A1 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175852-A1 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | CHEK1, CHEK2, CDKN1A | MAPKAPK2 43/4885CHEK1 1/4885JAK2 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.